|
|
Biography |
|
|
Christopher C Hentschel is the former president and CEO of the Swiss Foundation Medicines for Malaria Venture, MMV and has recently joined Bio City Development Co as a partner. His immediate role in this capacity is to support the establishment of a world class partnership based science base at Bio Istanbul, a $2 billion biomedical science park in Turkey. Under his guidance MMV became the global leader in malaria drug discovery and development and as a scalable, global public-private-partnership it remains an important paradigm for biomedical innovation targeted at the production of global public goods. Dr Hentschel also has considerable experience in adding value to purely private sector biomedical research efforts. He served as Senior Vice President and Chief Scientific Officer of Centocor, known for its pioneering cardiovascular and autoimmune drugs Reopro and Remicade. He was instrumental in Centocor’s merger with J&J in 1999 and served as chairman of the company’s scientific advisory board. Dr Hentschel's breadth of experience in adding societal and economic value through biomedical innovation is widely recognized and he has been a regular contributor to relevant high level fora namely the World Economic Forum meetings in Davos, the Global Medical Forum meetings in Zurich and the Abu Dhabi, and Biovision in Lyon. He is currently a board member of several for-profit and not-for profit organizations.
|
|
|
|
|
|
|
Abstract |
|
|
|
|
Global Public-Private-Partnership and BioCities - societal value through biomedical nnnovation |
|
|
|
|
|
|
|
|